Oral Valiltramiprosate in APOEε4/ε4 Carriers with Early Alzheimer’s Disease: Insights from the Phase III APOLLOE4 Trial

Valiltramiprosate, a potent inhibitor of amyloid-β oligomer formation, was tested in a 78-week phase III trial in APOEε4/ε4 homozygotes with early Alzheimer’s disease (AD).
The overall study population showed significant slowing of hippocampal atrophy but no significant clinical improvement on the primary cognitive endpoint.
Prespecified analyses in the mild cognitive impairment (MCI) subgroup demonstrated nominally significant slowing in cognitive decline and functional measures alongside imaging benefits.
The treatment was generally well tolerated, with mainly gastrointestinal adverse events and no increased risk of amyloid-related imaging abnormalities (ARIA).

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Valiltramiprosate, a potent inhibitor of amyloid-β oligomer formation, was tested in a 78-week phase III trial in APOEε4/ε4 homozygotes with early Alzheimer’s disease (AD).
The overall study population showed significant slowing of hippocampal atrophy but no significant clinical improvement on the primary cognitive endpoint.
Prespecified analyses in the mild cognitive impairment (MCI) subgroup demonstrated nominally significant slowing in cognitive decline and functional measures alongside imaging benefits.
The treatment was generally well tolerated, with mainly gastrointestinal adverse events and no increased risk of amyloid-related imaging abnormalities (ARIA).

Sign in free to continue reading